摘要
目的探讨司库奇尤单抗治疗中重度斑块状银屑病的临床效果及安全性.方法选取2019年6月—2021年10月我院收治的84例中重度斑块状银屑病患者,按随机数字表法分为两组,每组42例.对照组采用复方丙酸氯倍他索软膏治疗,观察组在对照组基础上加用司库奇尤单抗治疗,均用药4周.比较两组的临床疗效、银屑病面积与严重性指数(PASI)评分、皮损症状评分、炎症水平、生活质量及安全性.结果观察组的治疗总有效率为95.24%,高于对照组的80.95%,差异有统计学意义(P<0.05).观察组治疗后的PASI评分及各项皮损症状评分均低于对照组,组间差异有统计学意义(P<0.05).观察组治疗后的肿瘤坏死因子-α、白细胞介素-17水平均低于对照组,组间差异有统计学意义(P<0.05).观察组治疗后的各项生活质量评分均高于对照组,组间差异有统计学意义(P<0.05).两组的不良反应发生率比较,差异无统计学意义(P>0.05).结论司库奇尤单抗可提高中重度斑块状银屑病的治疗效果,降低PASI评分,加快炎症水平复常,减轻疾病对患者生活的影响,安全可靠.
Objective To investigate the clinical effect and safety of Secukinumab in the treatment of moderate to severe plaque psoriasis.Methods A total of 84 patients with moderate to severe plaque psoriasis who were admitted to our hospital from June 2019 to October 2021 were selected and were divided into two groups according to the random number table method,with 42 cases in each group.The control group was treated with compound clobetasol propionate ointment,and the observation group was treated with Secukinumab in addition to the control group.Both groups were treated for 4 weeks.The clinical efficacy,psoriatic area and severity index(PASI)score,psoriatic symptom score,inflammation level,quality of life and safety were compared between the two groups.Results The total effective rate of observation group was 95.24%,higher than 80.95%of control group,the difference was statistically significant(P<0.05).The PASI score and various lesions symptom scores of the observation group were lower than those of the control group after treatment,and the differences between the groups were statistically significant(P<0.05).The levels of tumor necrosis factor-αand interleukin-17 in the observation group after treatment were lower than those in the control group after treatment,the differences between the groups were statistically significant(P<0.05).The scores of quality of life in the observation group after treatment were higher than those in the control group,and the differences between the groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Secukinumab can improve the therapeutic effect of moderate and severe plaque psoriasis,reduce PASI score,accelerate the recovery of inflammation level,and reduce the impact of the disease on patients’life,which is safe and reliable.
作者
王欣
梅玉霞
孙欣
李娜
WANG Xin;MEI Yuxia;SUN Xin;LI Na(The Ward of Department of Traditional Chinese Medicine of Dermatology,Affiliated Hospital of Binzhou Medical College,Binzhou Shandong,256600,China)
出处
《反射疗法与康复医学》
2022年第7期112-115,共4页
Reflexology And Rehabilitation Medicine
作者简介
王欣(1988-),女,山东德州人,本科,主管护师,研究方向:皮肤、中医、耳鼻喉科常见病护理;通信作者:李娜(1981-),女,山东滨州人,本科,主管护师,研究方向:护理管理、重症护理、皮肤护理、中医护理,邮箱:Incja@sina.com。
